Photocure (PHO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Photocure (PHO) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr26.43 Million ≈ $2.78 Million USD) by net assets (Nkr486.60 Million ≈ $51.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PHO defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Photocure - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Photocure's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Photocure Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Photocure ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Surgical Science Sweden AB
ST:SUS
|
0.017x |
|
Mainstreet Bank
NASDAQ:MNSB
|
0.031x |
|
QINGCI GAMES INC. -00001
F:Z56
|
N/A |
|
Black Spade Acquisition III Co
NYSE:BIII
|
-0.002x |
|
Flutter Entertainment PLC
LSE:FLTR
|
0.034x |
|
Atlan Holdings Bhd
KLSE:7048
|
0.149x |
|
Dynamic Cables Limited
NSE:DYCL
|
0.011x |
|
Bjorn Borg AB
ST:BORG
|
0.364x |
Annual Cash Flow Conversion Efficiency for Photocure (2002–2024)
The table below shows the annual cash flow conversion efficiency of Photocure from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see Photocure market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr501.72 Million ≈ $52.79 Million |
Nkr76.75 Million ≈ $8.08 Million |
0.153x | +151.36% |
| 2023-12-31 | Nkr482.85 Million ≈ $50.81 Million |
Nkr29.39 Million ≈ $3.09 Million |
0.061x | +1495.53% |
| 2022-12-31 | Nkr462.73 Million ≈ $48.69 Million |
Nkr-2.02 Million ≈ $-212.35K |
-0.004x | -109.18% |
| 2021-12-31 | Nkr502.63 Million ≈ $52.89 Million |
Nkr23.89 Million ≈ $2.51 Million |
0.048x | +54.94% |
| 2020-12-31 | Nkr508.13 Million ≈ $53.47 Million |
Nkr15.59 Million ≈ $1.64 Million |
0.031x | -69.03% |
| 2019-12-31 | Nkr208.59 Million ≈ $21.95 Million |
Nkr20.66 Million ≈ $2.17 Million |
0.099x | +172.38% |
| 2018-12-31 | Nkr176.34 Million ≈ $18.56 Million |
Nkr-24.12 Million ≈ $-2.54 Million |
-0.137x | -26.45% |
| 2017-12-31 | Nkr218.08 Million ≈ $22.95 Million |
Nkr-23.59 Million ≈ $-2.48 Million |
-0.108x | -242.01% |
| 2016-12-31 | Nkr251.94 Million ≈ $26.51 Million |
Nkr19.19 Million ≈ $2.02 Million |
0.076x | +176.09% |
| 2015-12-31 | Nkr210.06 Million ≈ $22.10 Million |
Nkr-21.03 Million ≈ $-2.21 Million |
-0.100x | -294.80% |
| 2014-12-31 | Nkr240.06 Million ≈ $25.26 Million |
Nkr-6.09 Million ≈ $-640.63K |
-0.025x | +93.16% |
| 2013-12-31 | Nkr269.12 Million ≈ $28.32 Million |
Nkr-99.72 Million ≈ $-10.49 Million |
-0.371x | -156.53% |
| 2012-12-31 | Nkr380.27 Million ≈ $40.02 Million |
Nkr-54.93 Million ≈ $-5.78 Million |
-0.144x | -84.12% |
| 2011-12-31 | Nkr439.34 Million ≈ $46.23 Million |
Nkr-34.47 Million ≈ $-3.63 Million |
-0.078x | -330.80% |
| 2010-12-31 | Nkr458.85 Million ≈ $48.28 Million |
Nkr15.60 Million ≈ $1.64 Million |
0.034x | -95.55% |
| 2009-12-31 | Nkr415.78 Million ≈ $43.75 Million |
Nkr317.44 Million ≈ $33.40 Million |
0.763x | +355.48% |
| 2008-12-31 | Nkr199.69 Million ≈ $21.01 Million |
Nkr-59.68 Million ≈ $-6.28 Million |
-0.299x | +18.77% |
| 2007-12-31 | Nkr259.99 Million ≈ $27.36 Million |
Nkr-95.66 Million ≈ $-10.07 Million |
-0.368x | -281.35% |
| 2006-12-31 | Nkr326.94 Million ≈ $34.40 Million |
Nkr66.33 Million ≈ $6.98 Million |
0.203x | +113.94% |
| 2005-12-31 | Nkr48.47 Million ≈ $5.10 Million |
Nkr-70.54 Million ≈ $-7.42 Million |
-1.455x | -147.85% |
| 2004-12-31 | Nkr85.57 Million ≈ $9.00 Million |
Nkr-50.25 Million ≈ $-5.29 Million |
-0.587x | -9.86% |
| 2003-12-31 | Nkr131.90 Million ≈ $13.88 Million |
Nkr-70.51 Million ≈ $-7.42 Million |
-0.535x | -75.36% |
| 2002-12-31 | Nkr167.00 Million ≈ $17.57 Million |
Nkr-50.91 Million ≈ $-5.36 Million |
-0.305x | -- |
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more